Active Ingredient History
Apatinib, also known as rivoceranib, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2. It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically, apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma of Lung (Phase 2)
alpha-Fetoproteins (Phase 2)
Angiogenesis Modulating Agents (Phase 2)
Ascites (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Biomarkers (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 4)
Capecitabine (Phase 3)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Catheters (Phase 2)
Chemoembolization, Therapeutic (Phase 2)
Cholangiocarcinoma (Phase 3)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Cytochrome P-450 Enzyme System (Phase 1)
Death (Phase 1)
Digestive System Neoplasms (Phase 3)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 2)
Drug Therapy, Combination (Phase 1/Phase 2)
Endothelium (Phase 2)
Epidermal Growth Factor (Phase 3)
Esophageal Neoplasms (Phase 4)
Esophageal Squamous Cell Carcinoma (Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Gallbladder Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 3)
Gestational Trophoblastic Disease (Phase 2)
Glioma (Phase 2)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hepatectomy (Phase 2)
Hypopharyngeal Neoplasms (Phase 2)
Immune Checkpoint Inhibitors (Phase 3)
Immunotherapy (Phase 2)
Intestinal Neoplasms (Phase 2)
Lapatinib (Phase 3)
Liver Neoplasms (Phase 2)
Liver Transplantation (Phase 1/Phase 2)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 4)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 4)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, T-Cell (Phase 4)
Medulloblastoma (Phase 2)
Melanoma (Phase 2)
Microsatellite Instability (Phase 2)
Molecular Targeted Therapy (Phase 2)
Mouth Neoplasms (Phase 1)
Mutation (Phase 2)
Nasopharyngeal Carcinoma (Phase 2/Phase 3)
Nasopharyngeal Neoplasms (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 4)
Neuroblastoma (Phase 2)
Osteosarcoma (Phase 2/Phase 3)
Ovarian Neoplasms (Phase 4)
Pancreatic Neoplasms (Phase 2)
Pharmacokinetics (Phase 2)
Progression-Free Survival (Phase 3)
Radiation Injuries (Phase 2)
Radiotherapy (Phase 2)
Recurrence (Phase 2)
Respiratory Tract Diseases (Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Diseases (Phase 3)
Stomach Neoplasms (Phase 4)
Survival (Phase 2)
Thoracic Neoplasms (Phase 2)
Thyroid Gland (Phase 2)
Thyroid Neoplasms (Phase 3)
Triple Negative Breast Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 4)
Uterine Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue